In breast cancer, for example, both control of HER-2/ErbB2 oncogenes expression and the marked frequency of mutant isoforms of FOXP3 indicate that FOXP3 is an important suppressor of the carcinogenic condition (175); in a study in which 68.5% of the patients with prostate cancer expressed FOXP3, FOXP3 behaved as a tumor suppressor. This evidence concerns the gene ERBB2 and breast carcinoma.